ROCKVILLE, MD, April 28, 2016 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for rhCC10 (recombinant human Club Cell 10 kDa Protein), specifically for the prevention of chronic lung disease related to premature birth.

Read more here